These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16515882)

  • 1. Entecavir: a new treatment option for chronic hepatitis B.
    Zoulim F
    J Clin Virol; 2006 May; 36(1):8-12. PubMed ID: 16515882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entecavir for the treatment of chronic hepatitis B virus infection.
    Matthews SJ
    Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
    Sims KA; Woodland AM
    Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of entecavir in the treatment of chronic hepatitis B infection.
    Rivkin A
    Curr Med Res Opin; 2005 Nov; 21(11):1845-56. PubMed ID: 16307706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir for chronic hepatitis B: a review.
    Palumbo E
    Ther Drug Monit; 2008 Feb; 30(1):1-4. PubMed ID: 18223455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B: a wider range of therapeutic options.
    Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
    Cheng PN; Chang TT
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir: new drug. Chronic hepatitis B: a last resort.
    Prescrire Int; 2007 Oct; 16(91):183-5. PubMed ID: 17926822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
    AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
    Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
    J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
    Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
    Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
    Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
    J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
    Rivkin A
    Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Entecavir - options and obstacles of an effective treatment for chronic hepatitis B].
    Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2010 Jan; 135(1-2):32-7. PubMed ID: 20024882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.